Physiomics Share Price | |
---|---|
Price | 1.35 |
Bid | 1.30 |
Ask | 1.40 |
Change | 0.00 (0.00%) |
Volume | 513,287 |
Open | 1.35 |
High | 1.35 |
Low | 1.35 |
Prev. Close | 1.35 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £1.83m |
Market Size | 75,000 |
52 Week High | 3.10 |
52 Week High Date | 25-Sep-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 7 |
---|---|
Vol. Sold | 300,000 |
Sold Value | £3.99k |
Vol. Bought | 213,287 |
Bought Value | £2.98k |
PE Ratio | -2.755102 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
08-May-24 | 11:36:22 | 1.33 | 200,000 | Sell* | 1.30 | 1.40 | 2,660 | O Ordinary |
08-May-24 | 11:35:44 | 1.389 | 15,000 | Buy* | 1.30 | 1.40 | 208.35 | O Ordinary |
08-May-24 | 11:34:18 | 1.331 | 300,000 | Sell* | 1.30 | 1.40 | 3,993 | O Ordinary |
08-May-24 | 11:23:41 | 1.39 | 25,000 | Buy* | 1.30 | 1.40 | 347.50 | O Ordinary |
08-May-24 | 09:17:10 | 1.391 | 1 | Buy* | 1.30 | 1.40 | 0.01 | O Ordinary |
08-May-24 | 08:23:23 | 1.40 | 20,000 | Buy* | 1.30 | 1.40 | 280.00 | O Ordinary |
08-May-24 | 08:14:03 | 1.40 | 100,000 | Buy* | 1.30 | 1.40 | 1,400 | O Ordinary |
08-May-24 | 08:00:15 | 1.40 | 53,286 | Buy* | 1.30 | 1.40 | 746.00 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour™ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.